Amyloid pathology in cognitively normal elderly subjects (PreclinAD)
EU CTIS ID: 2024-518559-41-01
What this study is testing
To validate known and to discover novel diagnostic markers and risk factors for amyloid pathology in cognitively normal subjects and to validate known and to discover novel predictors for cognitive decline in cognitively normal subjects with amyloid pathology.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- In order to be eligible to participate in this study, a participant must meet all of the following criteria: Age 60-100 years Telephone Interview for Cognitive Status modified (TICS-m) >22 (de Jager, Budge et al. 2003) Geriatric Depression Scale (GDS) (15 item) <11(Yesavage, Brink et al. 1982) Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 10 word list immediate and delayed recall (> -1.5 SD of age adjusted normative data) (Morris, Heyman et al. 1989) Clinical Dementia Rating (CDR) scale of 0 with a score on the memory sub domain of 0 (Morris 1993)
You likely can't join if
- A potential participant who meets any of the following criteria will be excluded from participation in this study: Clinical diagnosis of mild cognitive impairment or probable AD Severe head trauma, with loss of consciousness Brain tumour (past, present) Schizophrenia, bipolar disorders, or recurrent psychotic disorders Stroke resulting in physical impairment Neurodegenerative disorders (e.g. Huntington disease, cortical basal degeneration, multiple system atrophy, Creutzfeldt-Jacob disease, primary progressive aphasia, Parkinson’s disease) Epilepsy, currently using antiepileptic drugs (AEDs) Brain infection (e.g. herpes simplex encephalitis) Cancer with terminal life expectancy Known B12 vitamin deficiency without treatment Uncontrolled diabetes mellitus Known thyroid disease without treatment History of recreational drug use Alcohol consumption: >35 units per week Physical morbidity or illness which will not permit attendance at visit sessions Contraindication for MRI (e.g. metal implants, pacemaker etc.) Medications that may impair cognition, at the discretion of the investigator, e.g.: o High dose benzodiazepine o Lithium carbonate o Antipsychotics including atypical agents o High dose antidepressants o Parkinson’s disease medicines
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.